Insider · CIK 0001378589
Mary Kay Fenton
Files at CGEM (Cullinan Therapeutics, Inc.). First filing Feb 23, 2026, latest Feb 23, 2026.
In brief
Mary Kay Fenton files SEC Form 4 as CFO at CGEM (Cullinan Therapeutics, Inc.). Since Feb 23, 2026, Mary Kay Fenton has reported 0 open-market buys worth $0 and 1 open-market sell worth $60k, the latest filed on Feb 23, 2026.
A track record needs three past buys with six months of prices behind them; Mary Kay Fenton has 0, so none is measured yet.
The newest scored trade: sold $60k of CGEM on Feb 20, 2026, filed Feb 23, 2026, scored 44 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $60k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CGEM: Cullinan Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Cullinan Therapeutics, Inc. | $60k 4,398 shares | -3% | +137% from low-2% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +1,541 | $8.60 | $13k | 127,921 | Jul 2, 2026 |
| Feb 20, 2026 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -4,398 | $13.62 | $60k | 126,380 | Feb 23, 2026 |
| Feb 18, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +68,750 | $0.00 | $0 | 130,778 | Feb 19, 2026 |
| Feb 18, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +137,500 | $0.00 | $0 | 137,500 | Feb 19, 2026 |
| Dec 31, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +27 | $6.49 | $175 | 62,028 | Jan 5, 2026 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 60,000 | Feb 21, 2025 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 21, 2025 |
Questions about Mary Kay Fenton
Answered from the filings on this page, as of the latest one.
Is Mary Kay Fenton buying or selling?
In the last 12 months Mary Kay Fenton reported 0 open-market buys worth $0 and 1 open-market sell worth $60k on SEC Form 4; the latest was sold $60k of CGEM on Feb 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Mary Kay Fenton's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mary Kay Fenton has 0.
Where does Mary Kay Fenton file Form 4?
Mary Kay Fenton has filed Form 4 at CGEM (Cullinan Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.